April 23, 2015Diabetes and Vascular Disease Research
Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction
Key Points
- To delineate the role of diabetes mellitus and asymptomatic diabetic cardiomyopathy as early stages in the progression toward heart failure with preserved ejection fraction.
- Reviewed clinical paradigms defining the transition of heart failure across Stages A through D.
- Analyzed the pathophysiology of left ventricular diastolic dysfunction in diabetic patients without coronary artery disease, hypertension, or alternative etiologies.
- Characterizes diabetes mellitus as a Stage A risk factor and asymptomatic diabetic cardiomyopathy as Stage B heart failure with preserved ejection fraction (HFpEF).
- Identifies elevated diastolic stiffness and left ventricular diastolic dysfunction as defining features placing patients at high risk of progressing to symptomatic Stage C HFpEF.
- Emphasizes the clinical necessity of early recognition of the diabetic cardiomyopathy phenotype to facilitate targeted preventive interventions.
Structured PICO
P
Population
Diabetic patients without coronary artery disease, hypertension or other potential aetiologies (asymptomatic diabetic cardiomyopathy)
Diabetic cardiomyopathy should be recognized as stage B HFpEF to enable targeted risk management and preventive strategies.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Hypothesis-generating for preventive strategies in diabetic cardiomyopathy; prospective validation required before practice change.
Cite This Study
Carolyn S.P. Lam (2015) studied this question.